In disclosing last week’s “negative trend vote” by the European Medicines Agency’s human drugs committee (CHMP) on EU approval of their Alzheimer’s drug aducanumab, Biogen, Inc. and Eisai Co., Ltd. join the lengthening list of companies that have gone against the EMA’s advice not to divulge such information.
The vote, which signals that the CHMP is unlikely to recommend marketing authorization for aducanumab at its next monthly meeting...








